Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Current Leases (2022 - 2025)

Historic Current Leases for Taysha Gene Therapies (TSHA) over the last 4 years, with Q3 2025 value amounting to $1.7 million.

  • Taysha Gene Therapies' Current Leases fell 809.92% to $1.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.7 million, marking a year-over-year decrease of 809.92%. This contributed to the annual value of $1.9 million for FY2024, which is 1403.4% up from last year.
  • According to the latest figures from Q3 2025, Taysha Gene Therapies' Current Leases is $1.7 million, which was down 809.92% from $1.7 million recorded in Q2 2025.
  • Over the past 5 years, Taysha Gene Therapies' Current Leases peaked at $1.9 million during Q4 2024, and registered a low of $1.5 million during Q4 2022.
  • Its 4-year average for Current Leases is $1.7 million, with a median of $1.7 million in 2024.
  • As far as peak fluctuations go, Taysha Gene Therapies' Current Leases skyrocketed by 1801.04% in 2024, and later tumbled by 809.92% in 2025.
  • Quarter analysis of 4 years shows Taysha Gene Therapies' Current Leases stood at $1.5 million in 2022, then rose by 8.22% to $1.6 million in 2023, then rose by 14.03% to $1.9 million in 2024, then decreased by 11.13% to $1.7 million in 2025.
  • Its Current Leases was $1.7 million in Q3 2025, compared to $1.7 million in Q2 2025 and $1.8 million in Q1 2025.